In 'Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD,' our experts delve into the practical realities of accessing advanced lipid-lowering therapies in the United States, where insurance coverage for PCSK9 inhibitors varies considerably across commercial plans, Medicaid, and Medicare. The panel distinguishes between Medicare Part B and Part D coverage structures, noting that inclisiran tends to fare better under Part B while monoclonal antibodies such as evolocumab and alirocumab are subject to the more variable Part D formulary landscape, often requiring prior authorization and generating significant administrative burden for clinical practices. One panelist describes training a dedicated staff member to manage insurance denials and appeals, reflecting the reality that securing guideline-directed therapy for high-risk patients frequently demands substantial practice resources. The panel also highlights an emerging third pathway for access, noting that some manufacturers are beginning to offer direct-to-patient programs at reduced prices, with monoclonal antibody costs dropping to approximately half of retail price in some cases, though even these reduced costs remain out of reach for many patients.

The conversation then shifts to shared decision-making as a cornerstone of long-term adherence, with the panel referencing survey data from studies of 5,000 and 10,000 statin-prescribed patients showing that a key predictor of self-reported adherence was whether patients felt genuinely consulted and included in the treatment decision by their prescriber. The panelists acknowledge that time constraints in clinical practice can make thorough shared decision-making difficult, but argue that the investment pays dividends in long-term patient buy-in and persistence with therapy. The episode closes with a candid discussion about the challenge of health misinformation, with the panel encouraging clinicians to proactively acknowledge that much of what patients encounter online about medications is unreliable, and to position themselves as trusted partners in the patient's health journey, emphasizing that the personal connection between prescriber and patient remains one of the most powerful tools available in supporting adherence and achieving lasting ASCVD risk reduction.

Our last episode, 'Closing Thoughts on ASCVD Management,' further explores ASCVD, highlighting the critical steps needed to bridge the persistent gap between guideline-recommended LDL goals and real-world clinical outcomes, with panelists offering forward-looking recommendations spanning healthcare system reform, risk assessment tools, treatment algorithms, patient engagement, and the foundational importance of long-term follow-up and adherence.